Clinical trial · Interventional
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
NCT04424719CI-TRIAL-00094454SALOMErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uveal Melanoma | Uveal Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with uveal melanoma
- description
- High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. For enucleated patients, a blood sample is required according to the study schedule.
- interventionNames
- Other: Blood test
Primary outcomes (3)
- measure
- Description of the metastatic events and treatments in high risk UM patients and correlation to biomarkers
- timeFrame
- 120 months
- description
- metastatic events and treatments reports correlation with their ocrresponding biomarquers
- measure
- Biological study (lymphocytes)
- timeFrame
- 120 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient aged of 18 years or more. 2. Patient with uveal melanoma with high metastatic relapse risk defined as : * T2b/c/d ou ≥ T3, * or chromosom 3 or chromosom 8 abnormality by CGH array. 3. Completion of treatment of the primary tumor ≤ 2 months. 4. Patient able to comply with the schedule of visits and blood samples of the study. 5. Signed informed consent form or legal representative. Exclusion Criteria: 1. Patient without french social insurance. 2. Any social, medical or psychological condition making the research process impossible.
References
Publications (0)
Data not yet available
No reference posted for this study.